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I
nfliximab is highly effective and relatively safe for the
treatment of patients with rheumatoid arthritis (RA) in
clinical trials.1–5 This prospective cohort study was under-
taken to determine adverse events, in particular, infections in
patients with RA treated with infliximab in daily clinical
practice.
METHODS AND RESULTS
We treated 168 patients with RA between 1 April 2000 and 1
October 2002, 82% female, with a median disease duration of
10 years (range 1–49). Inclusion criteria were 28 joint count
Disease Activity Score (DAS28) of .3.5 and failure of two
disease modifying antirheumatic drugs, including metho-
trexate. Patients with heart failure or with a malignancy
5 years before screening were excluded. After the alert about
tuberculosis,6 patients starting with infliximab treatment
were screened for that disease.
All patients were treated with an initial infliximab dose of
3 mg/kg (weeks 0, 2, 6, and subsequently, every 8 weeks).
When the response was insufficient—that is, a decrease in
DAS28 ,1.2 compared with baseline on two subsequent
occasions, the dose could be increased to 7.5 mg/kg. The
median duration of treatment was 0.86 years (range 0–2.5);
the median number of infusions used was 7 (range 1–18).
Methotrexate and prednisone were used by 92% and 50% of
the patients, respectively.
Patients were systematically asked about events and,
explicitly, about infections at each visit. All events occurring
during the infliximab treatment period were interpreted as
adverse events.
The most common mild adverse event was short lived
headache. Early allergic reactions were seen in 12 patients
(0.08/patient-year), but none developed severe cardiopul-
monary problems. Some cases of heart failure (n=2),
neuropathy (n=1), and malignancy (n=2) were observed.
Two patients died during the study, one of a cerebrovascular
accident and one of unknown cause.
Patients frequently (43–57%, depending on the definition
used) had infections, most commonly from the upper
respiratory tract and the lower urinary tract (table 1). One
case of tuberculosis was seen. The number of clinically
important infections was 0.59/patient-year, whereas serious
infections were found in 0.08/patient-year.
Compared with patients receiving low dose infliximab,
significantly (p,0.05) more patients with the increased dose
had clinically important infections (including serious infec-
tions), but other adverse events, demographic characteristics,
and drug use between the groups were comparable. After
correction for treatment duration with infliximab, the rate of
clinical infections was significantly higher in the group
receiving the increased dose. However, after correction for
treatment duration, clinically important infections were not
significantly more common in the group receiving the
increased dose.
DISCUSSION
Our study has shown that infection is the most common
adverse event of infliximab treatment in daily practice.
Clinical infections and clinically important infections were
found more frequently in patients receiving high dose
infliximab, without proven causality.
The occurrence of infections in our study is in the same
range as that described in (randomised) clinical trials of
infliximab.1 3 5 7 However, the incidence of infection in our
study was much higher than those described in a population
based study of patients with RA not treated with infliximab,
64 versus 32 events per patient per year.8
There is evidence that a higher risk for infections occurs
with a higher RA activity.9 It is reasonable to suppose that
patients with a dose increase had greater disease activity than
those treated with only low dose infliximab. We are unable to
comment on whether the higher incidence of infections is
associated with a high disease activity or with the strong
immunosuppressive action of infliximab, or both.
Table 1 Occurrence of adverse events in 168 patients with RA treated with infliximab
Adverse events No (%) Events
Events/
patient/year
3 mg/kg infliximab (n = 132) 3R7.5 mg/kg infliximab (n = 36)
No (%) Events
Events/
patient/year No (%) Events
Events/
patient/year
Any adverse event 122 (73) 208 1.44 89 (67) 152 1.40 30 (83) 56 1.30
All infections* 96 (57) 153 1.06 69 (52) 109 1.01 27 (75) 44 1.02
Clinical infections 72 (43) 93 0.64 50 (38) 65 0.41 22 (61) 28 0.65
Clinically important infections` 60 (36) 85 0.59 42 (32) 59 0.55 18 (50) 26 0.60
Antibiotics (po) 50 (30) 74 0.51 35 (27) 51 0.47 15 (42) 23 0.53
Serious infections1 10 (6) 11 0.08 7 (5) 8 0.07 3 (8) 3 0.07
*All infections defined as: objective and non-objective infections as reported by patient, clinical physician, or general physician, including unconfirmed upper
respiratory tract infection and unconfirmed lower urinary tract infection; clinical infections as considered present by a physician—that is, sinusitis, upper
respiratory tract infection, pneumonia, pyelonephritis, bacteriaemia/septicaemia, lower urinary tract infection, gastroenteritis, skin and soft tissue infections with
relevant findings of physician; `clinically important infections as defined by objective infection, eventually requiring oral antibiotic treatment; 1serious infection as
defined by admission to hospital and/or requiring IV antibiotic treatment (in majority pneumoniae); difference significant, p value ,0.05.
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In conclusion, infliximab can be used safely in daily clinical
practice, but both doctors and patients should be aware of the
(infection) risks, especially in patients receiving a higher dose
(.3 mg/kg) of infliximab, in order to anticipate and
minimise these risks.
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egener’s granulomatosis is a systemic vasculitis
mainly affecting the lungs, nasal sinuses, and
kidneys. Treatment usually consists of cyclophos-
phamide (Cy) and steroids.1 High dose Cy with autologous
stem cell support could be an alternative treatment for
patients resistant to conventional treatment or requiring long
term immunosuppression with the risk of secondary malig-
nancy.2
CASE REPORT
We report on a 33 year old woman with chronic relapsing
sinusitis, pulmonary granuloma, and proteinuria with pro-
gressive renal insufficiency since 1988. Renal biopsy showed
necrotising glomerulonephritis, and biopsy of the nasal sinus
showed granuloma with necrotising vasculitis. Proteinase-3-
antineutrophil cytoplasmic antibodies (PR3-ANCA) were
detectable with a titre of 1/280. Despite treatment with Cy
(750 mg/m2 every 3 weeks, later 100 mg/day orally) and
steroids renal function deteriorated, and she underwent
dialysis from April 1995 to December 1998. Live kidney
transplantation from the patient’s sister matched for HLA
was performed in December 1998. Irrespective of ciclosporin
A (CSA), which was given as prophylaxis for host versus graft
reaction, she continuously needed immunosuppression with
Cy (orally, 100 mg/day) because of persistent disease activity
with relapsing pulmonary infiltrations. The transplanted
kidney remained unaffected.
A cumulative Cy dose of over 100 g was reached and in
view of the relapsing pulmonary granuloma and increasing
PR3-ANCA titres, which in our patient correlated well with
disease activity, stem cell mobilisation was performed in May
1999 with Cy 4 g/m2 followed by granulocyte-colony stimu-
lating factor 5 mg/kg for 10 days. Stem cell apheresis and
selection of CD34+ stem cells was performed using the
CliniMacs device on day 10. When PR3-ANCA titres increased
from 1/128 to 1/500 after 4 months, high dose immunosup-
pression with Cy 50 mg/kg days 1–4 and ATG 5 mg/kg days
1–4, followed by retransfusion of 2.826106 CD34+ cells/kg
body weight was given. The conditioning regimen was
chosen according to the protocol for aplastic anaemia.3
Marked clinical improvement was seen with a regression of
pulmonary infiltrates on chest x ray examination. Complete
haematological reconstitution was achieved on day 12 after
stem cell retransfusion. CSA was continued for renal graft
protection.
Five months after high dose Cy, the patient was admitted
with malaise, high grade fever, and pancytopenia. The PR3-
ANCA titre was 1/1000, but computed tomography scans of
the lungs and nasal sinuses were normal. An active Epstein-
Barr virus (EBV) infection was diagnosed by serology (IgG
and IgM). Polymerase chain reaction disclosed a high
plasmatic viral load with 1 270 000 EBV transcripts per
100 ng genomic DNA. Treatment with intravenous ganciclo-
vir and immunoglobulins led to resolution of all symptoms.
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